Treatment of uncomplicated gonorrhea in women with single-dose cefonicid.
The efficacy of cefonicid (1.0 g given in a single intramuscular dose) was assessed in 50 women with uncomplicated infections due to beta-lactamase-negative strains of Neisseria gonorrhoeae. Forty-three (96%) of 45 cervical infections but only 23 (82%) of 28 anorectal infections were eradicated; overall, 44 (90%) of 49 women were cured of anogenital gonorrhea. Cefonicid failed to eradicate six (55%) of 11 pharyngeal gonococcal infections and 17 (85%) of 20 endocervical infections with Chlamydia trachomatis. Cefonicid had good activity against N. gonorrhoeae in vitro; 41 (98%) of 42 isolates were inhibited by less than or equal to 1.0 micrograms/ml. However, because of its poor efficacy against anorectal and pharyngeal gonococcal infections, single-dose cefonicid is not suitable for the treatment of gonorrhea in women or homosexually active men.
D000293:Adolescent; D000328:Adult; D002435:Cefamandole / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015790:Cefonicid; D005260:Female; D006069:Gonorrhea / Q000188:drug therapy*; D006801:Humans; D007273:Injections, Intramuscular; D008826:Microbial Sensitivity Tests; D009344:Neisseria gonorrhoeae / Q000187:drug effects; D010608:Pharyngeal Diseases / Q000188:drug therapy / Q000209:etiology; D012002:Rectal Diseases / Q000188:drug therapy / Q000209:etiology; D002577:Uterine Cervical Diseases / Q000188:drug therapy / Q000209:etiology
D002435:Cefamandole; D015790:Cefonicid